相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association between sodium glucose co-transporter 2 inhibitors and incident glaucoma in patients with type 2 diabetes: A multi-institutional cohort study in Taiwan
Shih-Chieh Shao et al.
DIABETES & METABOLISM (2022)
Comparison of Sodium-Glucose Cotransporter 2 Inhibitors vs Glucagonlike Peptide-1 Receptor Agonists and Incidence of Dry Eye Disease in Patients With Type 2 Diabetes in Taiwan
Yu-Chen Su et al.
JAMA NETWORK OPEN (2022)
Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis
Chao Li et al.
DIABETES OBESITY & METABOLISM (2021)
Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan
Yu-Chen Su et al.
DIABETES OBESITY & METABOLISM (2021)
Anaemia and the risk of progression from non-proliferative diabetic retinopathy to vision threatening diabetic retinopathy
Yafeng Li et al.
EYE (2020)
Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study
Yoo-Ri Chung et al.
PLOS ONE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
Eun Hyung Cho et al.
JOURNAL OF DIABETES RESEARCH (2018)
Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy
Masarori Wakisaka et al.
GLYCOBIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up
J. Wilding et al.
PRIMARY CARE DIABETES (2017)
Accuracy of Billing Codes Used in the Therapeutic Care of Diabetic Retinopathy
Marisa Lau et al.
JAMA OPHTHALMOLOGY (2017)
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
Sophia Zoungas et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Blood pressure control for diabetic retinopathy
Diana V. Do et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2015)
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze et al.
PLOS ONE (2014)
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus
L. H. Chen et al.
DIABETES OBESITY & METABOLISM (2013)
Accuracy of International Classification of Diseases, Ninth Revision, Clinical Modification Billing Codes for Common Ophthalmic Conditions
Kelly W. Muir et al.
JAMA OPHTHALMOLOGY (2013)
Identification of patients with diabetic macular edema from claims data - A validation study
Srilaxmi Bearelly et al.
ARCHIVES OF OPHTHALMOLOGY (2008)
分享论文
